中国P站

Multi-modal cancer diagnostics; AI-integrated oncology diagnostics; Radiomics-pathomics integration; Multi-omics cancer biomarkers; Hybrid AI models in cancer detection; Deep learning in medical image fusion; Genomic and phenotypic data fusion; Digital pathology and radiology convergence; Precision oncology diagnostic pipelines; Image-omics integration in cancer diagnosis; Omics-informed tumor classification

Introduction

Cancer remains a leading cause of morbidity and mortality worldwide. Despite advances in detection and therapy, late diagnoses and tumor heterogeneity continue to present significant obstacles to effective treatment [1]. Traditional diagnostic modalities such as radiological imaging and histopathological examination offer valuable structural and morphological insights but often fail to capture the full complexity of tumor biology [2]. With the rise of precision medicine, there is an urgent need for diagnostic approaches that are not only accurate and early but also biologically informative [3]. The integration of diverse biomedical data types has emerged as a promising strategy to improve cancer diagnostics. Radiomics involves the extraction of quantitative features from medical images (e.g., CT, MRI, PET), while pathomics refers to computational analysis of digitized histopathological slides [4]. These techniques provide phenotypic data that can be correlated with genetic, epigenetic, transcriptomic, and proteomic information collectively referred to as multi-omics [4]. Each modality offers unique insights: radiomics captures tumor heterogeneity at the macro level, pathomics at the micro (cellular) level, and omics at the molecular level.

To address these limitations, integrative cancer diagnostics have emerged as a transformative approach. By combining radiomics, pathomics, and multi-omics features, hybrid diagnostic algorithms enable the convergence of macroscopic imaging, microscopic tissue characteristics, and molecular data into unified predictive models [5]. Radiomics transforms imaging data (like CT, MRI, or PET scans) into high-dimensional quantitative features, while pathomics leverages computational pathology to analyze histology slides for cellular and microarchitectural patterns [6]. When fused with genomic, transcriptomic, epigenomic, and proteomic profiles collectively referred to as multi-omics data, these models offer unprecedented insights into tumor biology, behavior, and therapeutic vulnerabilities [7].

The integration of these diverse data types is made possible by advances in artificial intelligence (AI) and machine learning (ML), particularly deep learning architectures capable of modeling complex non-linear relationships across modalities [8]. These hybrid systems are not only enhancing diagnostic accuracy but also facilitating early detection, subtype classification, prognosis estimation, and therapy selection in various cancers including lung, breast, colorectal, and gliomas.

Components of hybrid diagnostic models & clinical applications

In non-small cell lung cancer (NSCLC), combining CT-based radiomic features with gene expression profiles has improved early detection and subtyping. Integrative models have also helped predict EGFR mutation status and immunotherapy response. Integrating mammographic radiomics, histological features from digital slides, and transcriptomic data has enhanced the accuracy of differentiating between luminal A and triple-negative breast cancer subtypes, aiding in therapeutic decision-making. In brain tumors, particularly glioblastoma multiforme, hybrid algorithms have combined MRI-based texture features, histopathology image data, and methylation signatures (e.g., MGMT promoter) to predict tumor grade and recurrence. Hybrid models have been employed to improve staging and risk stratification using MRI, digital pathology, and genomic markers like KRAS and BRAF mutations. Combining modalities reduces false positives and negatives, improving overall diagnostic performance. Multi-omics data provides molecular context, allowing for patient-specific treatment strategies. Integration helps uncover latent disease signatures before they manifest in standard imaging or pathology. Explainable AI techniques can elucidate which features or modalities drive decisions. These models streamline workflows, reduce diagnostic delays, and alleviate the burden on clinical staff. Variability in data quality, format, and resolution across institutions requires robust preprocessing pipelines. Multi-modal data integration necessitates high-performance computing and advanced data storage solutions. Complex models can be difficult to interpret, raising concerns about clinical trust and transparency. Integrative algorithms must undergo rigorous validation to meet clinical and regulatory standards. Multi-omics data, especially when linked to images, raises concerns about patient re-identification and data governance.

Looking ahead, several innovations will shape the future of integrative cancer diagnostics:

Enables model training across institutions without data sharing, addressing privacy concerns. These models can simultaneously process different data types, capturing cross-modal interactions more effectively. Embedding integrative models into electronic health record (EHR) systems can facilitate point-of-care decision-making. Large, diverse datasets from national and international biobanks will be crucial for training and validating such algorithms. Transparency and informed consent protocols must evolve to include the use of integrated AI diagnostics.

Conclusion

Integrative cancer diagnostics using hybrid algorithms that combine radiomics, pathomics, and multi-omics data are reshaping the future of precision oncology. By unifying structural, cellular, and molecular information into a cohesive diagnostic framework, these models promise earlier, more accurate, and more personalized cancer detection and classification. Despite existing challenges, momentum is growing. With continued interdisciplinary collaboration, improved data-sharing frameworks, and investment in explainable AI technologies, hybrid diagnostic systems are poised to become key components of modern oncology practice. Looking ahead, the fusion of radiomics, pathomics, and multi-omics data offers the potential to transform cancer care from reactive to proactive, from one-size-fits-all to precision-guided, and from late-stage intervention to early-stage prevention.